Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Vanessa Klapp; Lorenzo Galluzzi

doi:10.1016/j.trecan.2021.11.006

Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Vanessa Klapp, Lorenzo Galluzzi^*

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › peer-review

Abstract

Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	Trends in Cancer
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/j.trecan.2021.11.006
Publication status	Published - Jan 2022
Externally published	Yes

Keywords

CGAS
PARP inhibitors
VEGFA
autophagy
immune checkpoint inhibitors
venetoclax

Access to Document

10.1016/j.trecan.2021.11.006

Cite this

@article{3bb495388a44444f8c129aedf06fc32c,

title = "Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma",

abstract = "Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.",

keywords = "CGAS, PARP inhibitors, VEGFA, autophagy, immune checkpoint inhibitors, venetoclax",

author = "Vanessa Klapp and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2022",

month = jan,

doi = "10.1016/j.trecan.2021.11.006",

language = "English",

volume = "8",

pages = "1--3",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

AU - Klapp, Vanessa

AU - Galluzzi, Lorenzo

PY - 2022/1

Y1 - 2022/1

N2 - Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

AB - Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

KW - CGAS

KW - PARP inhibitors

KW - VEGFA

KW - autophagy

KW - immune checkpoint inhibitors

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85120165119&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2021.11.006

DO - 10.1016/j.trecan.2021.11.006

M3 - Short survey

C2 - 34840109

AN - SCOPUS:85120165119

SN - 2405-8033

VL - 8

SP - 1

EP - 3

JO - Trends in Cancer

JF - Trends in Cancer

IS - 1

ER -

Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this